Paper Details

  1. Home
  2. Paper Details

Plecanatide Is Effective and Safe in the Treatment for Chronic Idiopathic Constipation: Results of a Phase II Trial.

Author: BarishCharles, DornSpencer, FogelRonald P, PatelReema, RosenbergJonathan

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Plecanatide, a pH-sensitive uroguanylin analog, is a new treatment option for chronic idiopathic constipation (CIC). It increases fluid and ion movement into the gastrointestinal lumen, softening stools and encouraging motility, while limiting the risk of diarrhea.
Paper Details　
Original Abstract of the Article :
Many patients with chronic idiopathic constipation (CIC) remain unsatisfied with their treatment options. Plecanatide is a pH-sensitive uroguanylin analog that increases fluid and ion movement into the gastrointestinal lumen, softening stools and encouraging motility, while limiting the risk of diar...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1007/s10620-020-06187-5

データ提供：米国国立医学図書館（NLM）

Plecanatide: A Novel Treatment for Chronic Idiopathic Constipation

Chronic idiopathic constipation (CIC) can be a challenging condition to manage, with many patients finding existing treatment options unsatisfactory. This study investigates the effectiveness and safety of plecanatide, a pH-sensitive uroguanylin analog, as a new treatment for CIC.

The study found that plecanatide effectively improved symptoms of CIC while minimizing the risk of diarrhea. This suggests that plecanatide could be a valuable new treatment option for patients struggling with CIC.

Plecanatide: A Promising New Option for Constipation Relief

This study offers hope for patients with chronic idiopathic constipation. Plecanatide's efficacy in improving symptoms while minimizing the risk of diarrhea presents a significant advancement in the treatment of this challenging condition.

Dr. Camel's Conclusion

This study is a testament to the tireless pursuit of innovative solutions in the field of medicine. Plecanatide offers a promising new option for patients with chronic idiopathic constipation. Its targeted mechanism of action and favorable safety profile make it a valuable addition to the treatment landscape.

Date :
  1. Date Completed 2021-04-28
  2. Date Revised 2021-04-28
Further Info :

Pubmed ID

32185662

DOI: Digital Object Identifier

10.1007/s10620-020-06187-5

Related Literature

Article Analysis
・Effects of plecanatide
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.